Will the second SGLT-2 insurance benefit decision form competition against DPP-4?
For the second time in the domestic market, a SGLT-2inhibitor is going to receive the health insurance from the 1st. The benefited drug is ‘Suglat(generic name: ipragliflozin). Its insured drug price will be KRW 705 per tab, applied when it is administered singular or in combination with metformi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
